Development

At CPHI Milan, Nicolas Camper, senior director—Bioconjugation Chemistry, Abzena, spoke about new developments in ADC technologies, including the role of complex chemistries.

Solving the challenge of better-stabilized temperature-sensitive biomolecules hinges on innovative formulation strategies.

At this year's CPHI Milan, Camille Dumont, PhD, manager, customer applications, Lonza, discussed current industry trends that are impacting oral solid dose formulation work.

At CPHI Milan, Stacey Treichler, senior director of global marketing and strategy, Purolite, an Ecolab company, spoke about current trends in the biopharma industry and innovations in purification resins .

During Bio 2024, Aaron Cowley, PhD, chief technical officer and co-founder, Captozyme, discussed the advancement in development of microbiome-derived therapeutics.

This premiere episode of Sexy Science in Pharmaceuticals features Professor Jonathan Pokorski, UC San Diego Jacobs School of Engineering, and Dr. James DiNunzio, Senior Principal Scientist at Merck & Co., Inc. in Rahway, NJ, discussing the benefits of hot-melt extrusion.

Webinar Date/Time: Thu, Oct 31, 2024 11:00 AM EDT

Webinar Date/Time: Session 1: Tue, Oct 22, 2024 11:00 AM EDT Session 2: Tue, Oct 22, 2024 2:00 PM EDT Session 3: Wed, Oct 23, 2024 2:00 PM JST

Innovative solutions are making personalized cell and gene therapies accessible to all.

Webinar Date/Time: Wed, Oct 16, 2024 11:00 AM EDT

Bringing promising ADC candidates to market faster hinges on the biopharma industry investing in linker design capabilities.

Emerging therapies, such as cell and gene therapies, come with unique challenges that must be planned for in advance.

Webinar Date/Time: Tue, Oct 8, 2024 11:00 AM EDT

Novo Nordisk will use Korro Bio’s OPERA platform to develop RNA editing candidates for two targets to treat cardiometabolic diseases.

Alternative delivery methods for biologics continues to be explored that offer less invasive, less painful administration.

Weighing development costs/resources and performance benefits is essential.

As the field of bioanalytical testing evolves, it is important for drug developers to stay at the forefront of the advancements to ensure they remain competitive.

With the completion of its acquisition of Morphic, Lilly expands its immunology pipeline to include Morphic's oral integrin therapies to address inflammatory bowel disease.

Webinar Date/Time: Thurs, September 19, 2024 Session 1: 9:00am EDT | 1:00pm GMT | 2:00pm CET Session 2: 1:00pm EDT| 5:00pm GMT | 6:00 am CET

Webinar Date/Time: Tue, Sep 17, 2024 11:00 AM EDT

Opaganib was given orphan drug designation for the treatment of neuroblastoma in children, which is rare, but the most common infancy malignancy.

The collaboration builds on Novartis’ acquisition of Chinook Therapeutics just over a year ago.

The approvals and authorizations come amid a late summer surge in the virus that is tracking a bit earlier than the early fall wave in the US in 2023.

The combination of Opdivo plus Yervoy is already established as a second-line treatment for patients with advanced hepatocellular carcinoma.

Under a deal worth potentially up to $1.3 billion, Merck, known as MSD outside of the United States and Canada, will acquire CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical.

Approximately 15% of all lung cancers diagnosed in the US are of the small-cell variety, and of those, 70% are considered extensive-stage.

Breyanzi demonstrated an overall high response rate in adults with relapsed or refractory follicular lymphoma in a Phase II study.

Genentech will leverage Sangamo’s proprietary capsid delivery platform and epigenetic regulation capabilities to develop genomic medicines to address certain neurodegenerative diseases.

National Institutes of Health’s National Institute of Allergy and Infectious Diseases collaborated with the University of Sciences, Techniques and Technologies of Bamako, Mali to conduct the trials.

The 94.3% efficacy of the Octapharma product was just a shade ahead of the 94.2% measured in a comparative product, Kcentra.